BioNTech Shares Under Pressure as Key Investor Exits
14.11.2025 - 14:20:05 | boerse-global.de
The German biotech firm BioNTech finds itself navigating turbulent waters following a significant divestment by its longtime collaborator. In a decisive overnight move, Pfizer sold its entire remaining stake of 4.55 million American Depositary Receipts (ADRs), sending a stark signal to the market and contributing to a sharp pre-market decline in the share price.
Pfizer’s decision to liquidate its entire position marks a pivotal moment for BioNTech. The shares were offloaded via a block trade at prices ranging from $108 to $111.70 per ADR. This is more than a simple portfolio rebalancing; it is widely interpreted as a clear vote of no confidence from a former ally in the company’s near-term Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen - Dreimal die Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
Für. Immer. Kostenlos.
US09075V1026 | BIONTECH | boerse | 68357556 |
